comparison of cost between two drugs in treatment of depression

Not Applicable

Recruiting

• Conditions: moderate depression

• Registration Number: CTRI/2014/03/004453
• Lead Sponsor: Moulya Nagraj

Brief Summary

Depression is the most common mood disorder affecting the population of all age groups with considerable impact on the quality of life with increased morbidity and mortality, imposing a great burden on the individual, family and society. The increasing prevalence of depression is of global concern regarding the cost of health care, loss of earning thus raising the interest in cost-benefit analysis in treating depression with the available therapies.

Even though depression can be treated by non-pharmacological methods like psychotherapy, electroconvulsive therapy and phototherapy, pharmacological approach remains the mainstay of the treatment. Currently, several classes of effective antidepressants are available such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and atypical antidepressants.

SSRIs are the generally preferred drugs as primary option because of their high efficacy, safety and tolerability. Escitalopram (S-enantiomer of citalopram) is one of the most widely prescribed SSRI because of its good tolerability and minimal drug interactive potential. Desvenlafaxine, an SNRI, is one of the most effective antidepressant, particularly for resistant depression, and also claimed to have additional therapeutic advantages. Both the drugs are known to have similar efficacy and few studies have been done in the Indian population to compare the cost-effectiveness and tolerability of these two drugs, hence the present study is taken up.

**Objectives of the Study**

To evaluate the cost-effectiveness of escitalopram and desvenlafaxine in treatment of moderate to severe depression.

To assess the tolerability and QoL of escitalopram and desvenlafaxine in the study subjects

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-01
• Last Update Posted: 2014-04-03

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• •Subjects of either gender aged between 18-65 years.
• •Subjects with first episode or recurrent episode of depression according to (ICD-10) with baseline score >18 and < 40 according to MADRS.
• •Willingness to give written informed consent and available for follow up.

Exclusion Criteria

• •Atypical depression •Postpartum depression •Pregnant women, breast feeding and women planning to conceive.
• •Subjects with severe depression requiring ECT and with high risk of suicidal tendency.
• •Co-morbid psychiatric illnesses •Previous history of epilepsy and sexual dysfunction •Serious or uncontrolled medical illness like glaucoma, hypertension, diabetes mellitus, hyperlipidemia, myocardial infarction, hepatic and renal impairment.
• •Depression secondary to medical illnesses, post traumatic depression.
• •Known history of allergy to both the study medications.
• •Participation in any other research study in recent past.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
reduction of MADRS score to 12 or by 50% from baseline scores and QoL is measured using 12-item short form of the Medical Outcomes Study questionnaire (SF-12)	baseline, 4week, 8 week, follow up

Secondary Outcome Measures

Name	Time	Method
Remission of scores by 50%	baseline,4 week, 8 week, follow up.

Trial Locations

Locations (1)

Kempegowda Institute of Medical Sciences; 🇮🇳 Bangalore, KARNATAKA, India

Kempegowda Institute of Medical Sciences

🇮🇳Bangalore, KARNATAKA, India

Dr Lakshmi Pandit

Principal investigator

8095481875

lvp4562@gmail.com